
HOME		SEARCH		RSS FEED		SUBSCRIBE

Search Results - cxxxxx

77 Results

Sort By:

Direct Reading Detection Kits for Surface Contamination by Anti-Neoplastic (Anti-Cancer) Drugs

Anti-neoplastic drugs, also known as anti-cancer drugs or chemotherapy, are used in the treatment of many types of cancer. However, these drugs are harmful to healthy cells as well as the cancerous cells. Exposure of healthcare workers to anti-neoplastic drugs from contaminated surfaces and drug vials in hospitals and pharmacies is a continuing problem...

Published: 7/25/2024 | Inventor(s): Deborah Sammons, Shirley Robertson, Jerome Smith

Keywords(s): AE1BXX, AE2XXX, AE3XXX, Anti-neoplastic, CANCER, CANCER CHEMOTHERAPY, CANCEROUS, CB5XXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, CDXXXX, Contaminant, Contaminants, Contaminated, contamination, CXXXXX, Detection, detection system, Direct, DRUGS, Kits, Listed LPM Surabian as of 4/15/2015, NIOSH, NIOSH-DART, Occupational health, OSHA, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Reading, SAFE, SAFETY, Surface, TOXIC, Toxicity, TOXIGENIC, TOXINS, VCXXXX, VPXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WMXXXX, WORKER, WORKER safety, XHXXXX, XIXXXX, YBXXXX, YEXXXX

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Research Equipment, TherapeuticArea > Cardiology, Application > Research Materials, Application > Occupational Safety and Health, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Consumer Products, TherapeuticArea > Dental, TherapeuticArea > Oncology, TherapeuticArea > Ophthalmology, TherapeuticArea > Endocrinology

Therapeutic, Bifunctional Janus Microparticles with Spatially Segregated Surface Proteins and Methods of Production

CDC researchers have developed a fabrication process to create bifunctional microparticles displaying two distinct proteins that are spatially segregated onto a single hemispheric surface. At present, there is no described way of producing biological microparticles with two distinct types of separated proteins. Bifunctional Janus particles generated...

Published: 4/8/2024 | Inventor(s): David White, Jennifer Tang, Todd Sulchek

Keywords(s): AAXXXX, ABXXXX, Asymmetrical, AXXXXX, Bi-Functionalized, CAXXXX, CBXXXX, CCXXXX, CDC Docket Import, CDC Docket Import NP, CXXXXX, DAXXXX, DBXXXX, DDXXXX, DEXXXX, DXXXXX, IAXXXX, IBXXXX, ICXXXX, IXXXXX, Microparticles, PXXXXX, VAXXXX, VBXXXX, VCXXXX, VDXXXX, VEXXXX, VFXXXX, VGXXXX, VHXXXX, VIXXXX, VJXXXX, VKXXXX, VLXXXX, VMXXXX, VOXXXX, VPXXXX, WAXXXX, WBXXXX, WIXXXX, WJXXXX, WKXXXX, WMXXXX, XAXXXX, XCXXXX, XDXXXX, XFXXXX, XHXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, Application > Consumer Products, TherapeuticArea > Cardiology, Application > Non-Medical Devices, TherapeuticArea > Neurology, TherapeuticArea > Oncology, TherapeuticArea > Dental, Application > Therapeutics, TherapeuticArea > Endocrinology, Application > Vaccines, TherapeuticArea > Immunology, TherapeuticArea > Ophthalmology, TherapeuticArea > Infectious Disease, Application > Software / Apps, TherapeuticArea > Geriatrics, Application > Medical Devices, ResearchProducts > Research Equipment, Application > Diagnostics, ResearchProducts > Antibodies, Application > Research Materials

Signatures of Genetic Control in Digestive and Liver Disorders

Our technology describes unique genetic signatures in patients with digestive diseases and liver disorders. Using comprehensive analysis of 735 microRNAs and 19,000 mRNAs, we have identified a unique set of microRNAs and/or mRNAs which predict disease phenotypes in patients with digestive and liver disorders. The identification of such point-of- care...

Published: 7/25/2024 | Inventor(s): Ralph Peace, Nicolaas Fourie, Sarah Abey, Wendy Henderson

Keywords(s): Acid, Altered, CAXXXX, CXXXXX, Digestive, DISORDERS, Expressions, IA3XXX, IAXXXX, IB3XXX, IBXXXX, Identification, IXXXXX, Listed LPM Vepa as of 4/15/2015, liver, MESSENGER, MICRO, miRNA, PHENOTYPE, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Ribonucleic, RNA, Species, THERAPY

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Immunology, Application > Diagnostics, Application > Research Materials, Application > Therapeutics, TherapeuticArea > Oncology

Generation of Artificial Mutation Controls for Diagnostic Testing

This technology relates to a method of generating artificial compositions that can be used as positive controls in a genetic testing assay, such as a diagnostic assay for a particular genetic disease. Such controls can be used to confirm the presence or absence of a particular genetic mutation. The lack of easily accessible, validated mutant controls...

Published: 7/25/2024 | Inventor(s): Laurina Williams

Keywords(s): AA1XXX, AA5XXX, AA6XXX, AAXXXX, ARTIFICIAL, AXXXXX, CA1AXX, CA1CXX, CA1XXX, CAXXXX, controls, CXXXXX, diagnostic, GAXXXX, GCXXXX, GXXXXX, IA1BXX, IA2XXX, IA3XXX, IA5XXX, IAXXXX, IXXXXX, MUTATION, NA2XXX, OA2XXX, TESTING, VPXXXX, WBXXXX, WHXXXX, WIXXXX, WMXXXX, XBXXXX, XCXXXX, XEXXXX, YAXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, Application > Software / Apps, Application > Diagnostics, TherapeuticArea > Dermatology, TherapeuticArea > Immunology, TherapeuticArea > Pulmonology, Application > Research Materials, TherapeuticArea > Ophthalmology, TherapeuticArea > Dental, Application > Therapeutics, TherapeuticArea > Endocrinology, Application > Consumer Products, TherapeuticArea > Oncology, TherapeuticArea > Neurology, ResearchProducts > Computational models/software, TherapeuticArea > Cardiology, TherapeuticArea > Infectious Disease

Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology

Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...

Published: 7/25/2024 | Inventor(s): Christopher Bachran, Stephen Leppla

Keywords(s): Anthrax, AnthraxToxins, CB1BXX, CB1XXX, CB3CXX, CB3XXX, CBXXXX, CXXXXX, fusion proteins, Patent Category - Biotechnology, THERAPY, toxin, tumor

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics

Engineered Anthrax Toxin Variants that Target Cancer

This technology describes the use of novel mutated anthrax protective antigen (PA) protein variants to target tumor cells and tumor vasculature. NIH scientists have engineered two PA variants that selectively complement one another and combine to form active octamers that target tumor cells. This controlled oligomeric activation of the PA proteins...

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Damilola Phillips, Clinton Leysath

Keywords(s): Anthrax, ANTIGEN, CB1BXX, CB1XXX, CBXXXX, COMPLEMENTARY, CXXXXX, ENGINEERED, exclusively, FORM, Octamers, Protective, That, toxin, VARIANTS

Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics, TherapeuticArea > Immunology

Pyruvate Kinase M2 Activators for the Treatment of Cancer

This technology describes a series of small-molecule activators of the pyruvate kinase M2 isoform (PK-M2). Pyruvate kinase (PK) is a critical metabolic enzyme that catalyzes the last step of the glycolytic pathway. It exists in several isoforms with different patterns of tissue expression. One isoform, PK-M2, is expressed in cells with a high rate...

Published: 7/25/2024 | Inventor(s): Jian-kang Jiang, Matthew Boxer, Min Shen, Douglas Auld, Craig Thomas

Keywords(s): Activator, ACTIVATORS, CANCER, CBXXXX, CXXXXX, Dimer, IBXXXX, ISOFORM, IXXXXX, M2, METABOLIC, METABOLITE, PK, PKM2, PK-M2, Proliferation, PYRUVATE, pyruvate kinase, small molecule, Tetramer, tumor

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, Application > Diagnostics, Application > Research Materials

Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology

Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Shihui Liu, Thomas Bugge, Diane Peters, Jie Liu, Alexander Wein, Kuang-Hua Chen, Christopher Bachran, Damilola Phillips, Henning Hansen, Sarah Arnett, Clinton Leysath

Keywords(s): Against, AMOUNTS, Anthrax, AnthraxToxins, ANTIGEN, B, CA1BXX, CB1AXX, CB1BXX, CB1XXX, CB3CXX, CBXXXX, Cells, Cell-Surface, CMG2, COMPLEMENTARY, CONTAIN, Containing, CXXXXX, Cytolethal, Distending, EFFICACY, Efficient, ENGINEERED, exclusively, Exploiting, FELINE, FELINE Leukemia, FORM, Fusion, fusion proteins, Having, High, IC2-PA, Identifying, Improved, Leppla, Listed LPM McCue as of 4/15/2015, MARKER, Metallo..., MULTIMERIC, Mutated, Nature, Octamers, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protective, Protein, proteins, SOLID, SPECIFICALLY, Specificity, Strong, TARGET, Targeting, That, THERAPY, toxin, TOXINS, tumor, Types, UAXXXX, VARIANTS, VASCULATURE, VETERINARY

Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Diagnostics, TherapeuticArea > Rare / Neglected Diseases

Highly Potent and Selective Deubiquitinating Enzyme Inhibitor

Available for licensing are inhibitors that target the USP1/ UAF1 deubiquitinating enzyme (DUB) complex. The FDA approval and commercial success of Velcade®, a small molecule proteasome inhibitor, has established the ubiquitin-proteasome system (UPS) as a valid target for anticancer treatment. However, proteasome inhibitors in general suffer from...

Published: 7/29/2024 | Inventor(s): Andrew Rosenthal, Ajit Jadhav, Thomas Dexheimer, Anton Simeonov, Qin Liang, Zhihao Zhuang, David Maloney

Keywords(s): CANCER, CANCER THERAPEUTICS, CB5XXX, CB7XXX, CBXXXX, Combination Therapy, CXXXXX, Deubiquitinase, Inhibitors, POTENT, protease inhibitors, SELECTIVE, small molecule, USP1/UAF1

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

mTOR Inhibition for the Prevention of Epithelial Stem Cell Loss and Mucositis

The integrity of the epidermis and mucosal epithelia is highly dependent on self-renewing stem cells and, therefore, is vulnerable to physical and chemical damage from common cancer treatments, such as radiation or chemotherapy. Consequently, many cancer patients undergoing these treatments develop mucositis, a debilitating condition involving painful...

Published: 7/25/2024 | Inventor(s): Ramiro Iglesias-Bartolome, Vyomesh Patel, Ana Cotrim, Alfredo Molinolo, James Mitchell, J Silvio Gutkind

Keywords(s): CBXXXX, Cell, CXXXXX, Epithelial, inhibition, mTOR, Mucositis, PREVENTS, PROTECTS, Radiation-induced, Senescence, Stem

Category(s): Application > Therapeutics, TherapeuticArea > Oncology

1 2 3 4 5 6 7 8

|

|

|

© 2024. All Rights Reserved. Powered by Inteum